Entrepreneur-in-Residence; EIR – Liquid Biopsy Services

The Company

We are Alloy Therapeutics — a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.

At Alloy, we believe our industry should compete on getting the best drugs to patients as quickly as possible, not exclusive access to the best platforms. As a reflection of our relentless commitment to the scientific community, we reinvest 100% of our revenue in innovation and access to innovation. MAY THE BEST DRUG WIN.

Alloy is headquartered in Waltham, MA with additional labs in Cambridge, UK;
Basel, Switzerland, and Athens, GA. Successful members thrive in our shared culture of accountability, deliberate trust, and open communication. As a team we aspire to work together to exceed expectations and collectively contribute across the global organization to always maintain our nimble, startup culture.

This is an on-site and full-time position in Waltham, MA. Alloy has an ethos of “Mentorship-By-Apprenticeship” in all of our positions. We strive to have workers in the office when needed to interact organically and face-to-face. Of course, as a lab-based operation, our cells and animals grow 7 days a week, 365 days per year. We respect and value our colleagues for their hard work that requires them to be in the lab every day.

We ask our people who have more flexible accommodations to appreciate their colleagues who have less flexibility. We are all one team!

The Office of the CEO at Alloy Therapeutics functions as a strategic thought partner across the executive leadership team. It drives and manages a broad range of corporate priorities to advance the Alloy ecosystem. The OCEO:

• Partners directly with C-suite leaders to facilitate high-priority initiatives.
• Coordinates execution across the company, aligning efforts across Business Development, Scientific, Legal, Finance, and Venture Creation.
• Delivers tools, processes, and analyses that support strategic decision-making and execution at all levels of the organization – including across Alloy and its affiliated venture studio, 82VS.

We are seeking an experienced Entrepreneur-in-Residence (EIR) to lead the development and launch of a clinical testing service focused on circulating tumor DNA (ctDNA) analysis in liquid biopsies. This role will be responsible for defining and implementing a differentiated service offering that leverages cutting-edge, ultra-high-sensitivity sequencing technologies to support oncology product development, translational research, and clinical decision-making.

The EIR will operate at the intersection of technology, clinical diagnostics, and business strategy, with the mandate to assess market opportunity, establish technical and operational foundations, and ultimately build a scalable clinical testing platform aligned with current and future oncology product offerings.

How You’ll Drive Impact

• Develop
  :
  The strategic vision, value proposition, and business model for a ctDNA-based clinical testing service.
• Lead
  :
  Selection, development, and implementation of high-sensitivity clinical testing assays.
• Drive
  :
  Establishment and scaling of CLIA/CAP-compliant clinical testing laboratories.
• Partner
  :
  With regulatory and payer experts to define reimbursement and commercial strategy.
• Collaborate
  :
  Closely with internal and external stakeholders to ensure clinical testing services are tightly aligned with Alloy Therapeutics’ broader drug development strategy.

Principal Responsibilities

Service & Business Development

• Define priority indications and clinical contexts where ctDNA provides clear decision-making value (e.g., MRD, therapy monitoring, resistance).
• Determine optimal platform strategy across assay development, sequencing technologies, and bioinformatics (build, partner, or acquire).
• Design…